Our Philadelphia Tysabri lawyers are evaluating cases involving serious injuries and death following treatment with the drug Tysabri. Tysabri is an intravenously (IV) administered medication used to treat multiple sclerosis (MS) and Crohn’s, both of which are autoimmune diseases. Tysabri works by altering the immune system function of MS and Crohn’s sufferers.
Tysabri has been linked to serious and sometimes deadly injuries, including:
- progressive multifocal leukoencephalopathy (PML)
- liver disease
- dangerous infections
Progressive Multifocal Leukoencephalopathy (PML)
Progressive multifocal leukoencephalopathy, or PML, is a brain infection caused by the JC virus that affects the white matter of the brain.
Because the virus attacks cells that produce myelin, a substance that protects nerve fibers in the brain, PML can disturb the function of any part of the body.
The JC virus is a common virus that generally leads to PML only in people who:
- are taking immune system suppressing drugs (such as Tysabri), or
- already have weakened immune systems
Inflammation that progresses over time damages a PML sufferer’s brain and frequently leads to severe disability or death. According to the National Institutes of Health (NIH), 30 to 50 percent of PML patients die within a few months of diagnosis. Survivors may sustain severe and ongoing neurological disabilities.
FDA Tysabri PML Warnings
The Tysabri-PML connection was suspected as early as 2005, when it was temporarily removed from the market after reports of PML in patients receiving Tysabri.
In February 2010, the FDA warned that the risk of developing PML from Tysabri use increases with the number of Tysabri infusions.
In April 2011, the FDA updated the Tysabri label with additional information about the risk of PML from Tysabri.
In January 2012, the FDA stated that the JC virus is a risk factor for PML and that the Tysabri label was updated to reflect the risk.
Tysabri PML Lawsuits
Lawsuits brought by Philadelphia Tysabri lawyers may allege that Tysabri manufacturers Biogen Idec, Inc. and Elan Pharmaceuticals, Inc.:
- produced and marketed an unreasonably dangerous drug
- knew or reasonably should have known of the risks of PML associated with Tysabri
- failed to adequately warn physicians and consumers of the risk of PML associated with Tysabri
- failed to adequately warn physicians and consumers of the increased risk of PML with prolonged use of Tysabri
Contact our Philadelphia Tysabri Lawyers
If you or a loved one developed PML or was otherwise injured after using Tysabri, you may be entitled to compensation from the manufacturer. Please contact our Philadelphia Tysabri lawyers, today, for a free evaluation of your case